Effectiveness of a Multicomponent Treatment Based on Pain Neuroscience Education, Therapeutic Exercise, Cognitive Behavioural Therapy, and Mindfulness in Patients With Fibromialgia (FIBROWALK STUDY): A Randomized Controlled Trial
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Fibromyalgia
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
- Enrollment
- 272
- Locations
- 1
- Primary Endpoint
- Revised Fibromyalgia Impact Questionnaire (FIQR)
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The main objective of this study is to analyse the effectiveness of the FIBROWALK multicomponent treatment program as coadjuvant of treatment-as-usual (TAU) compared to TAU alone.
Detailed Description
This is a two-arm RCT focused on the potential efficacy of the multicomponent program FIBROWALK as coadjuvant of treatment-as-usual (TAU) vs. TAU alone. FIBROWALK combines multicomponent approach based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness training. The main objective of this RCT was two-fold: (a) To analyse the effectiveness of a 12-week multicomponent treatment as an add-on to Treatment (FIBROWALK) as Usual (TAU) to improve functional impact (primary outcome), as well as pain, fatigue, kinesiophobia, physical function, anxiety, and depressive symptoms (secondary outcomes) compared to TAU; and (b) to explore the baseline differences between responders and non-responders in terms sociodemographic and clinical characteristics.
Investigators
Eligibility Criteria
Inclusion Criteria
- •fulfil the 2010/2011 American College of Rheumatology (ACR) FM diagnostic criteria. The diagnosis was verified by a rheumatologist (MA) of the CSSSU
- •adults \> 18 years old, and
- •provide written informed consent.
Exclusion Criteria
- •To have a terminal illnesses or programmed interventions that might interrupt the study.
- •No stringent eligibility criteria were established due to the naturalistic nature of the RCT. Excluding patients with lower education or comorbidities might have turned away many patients from our RCT who would otherwise be eligible, that is we put emphasis on external validity. All recruited patients were considered capable of following the multicomponent therapy if they were allocated to it. Lack of adherence to drugs or home activities was not an exclusion criterion given the nature of our trial and we analysed data from all participants who underwent random allocation. Treatment allocation was performed by the clinical trials unit in accordance with computer-generated randomisation sequences.
Outcomes
Primary Outcomes
Revised Fibromyalgia Impact Questionnaire (FIQR)
Time Frame: Through study completion, an average of 9 months
The FIQR comprises three dimensions: physical dysfunction (scores from 0 to 30), overall impact (scores from 0 to 20), and intensity of the symptoms (scores from 0 to 50) is used to measure the impact generated by FM during the last week. It consists of 21 items, which are answered on a numerical rating scale of 11 points (from 0 to 10). Total scores can range from 0 to 100, with higher scores reflecting greater deterioration.
Secondary Outcomes
- Tampa Scale for Kinesiophobia (TSK-11)(Through study completion, an average of 9 months)
- Hospital Anxiety and Depression Scale (HADS)(Through study completion, an average of 9 months)
- Visual Analog Scale (VAS) of the FIQR(Through study completion, an average of 9 months)
- Physical Function of the 36-Item Short Form Survey (SF-36)(Through study completion, an average of 9 months)